胰腺癌组织中血管内皮生长因子mRNA与尿激酶型纤溶酶原激活物mRNA定量表达的临床意义分析

席鹏程; 时开网; 朱响; 杨坤兴; 刘子君; 卞建民; 赵有财

doi:10.3969/j.issn.1001-5256.2014.08.014

胰腺癌组织中血管内皮生长因子mRNA与尿激酶型纤溶酶原激活物mRNA定量表达的临床意义分析

DOI: 10.3969/j.issn.1001-5256.2014.08.014

1. 南京医科大学附属南京医院肝胆胰外科
2. 南京医科大学附属南京医院病理科

基金项目:

南京市卫生局资助课题(YKK09067)；

详细信息

中图分类号: R735.9
计量
- 文章访问数: 2616
- HTML全文浏览量: 25
- PDF下载量: 524
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-16
- 出版日期: 2014-08-20

Analysis of clinical significance of quantitative expression of VEGF mRNA and uPA mRNA in pancreatic cancer tissue

Department of Hepatopancreatobiliary Surgery, Nanjing Hospital Affiliated to Nanjing Medical University

Research funding:

摘要

摘要: 目的探讨胰腺癌组织中血管内皮生长因子（VEGF）mRNA、尿激酶型纤溶酶原激活物（uPA）mRNA定量表达的临床意义。方法自2008年1月至2011年12月于本科行胰头癌根治术的患者中筛选出经病理证实为导管腺癌的30例患者的完整资料,采用荧光定量PCR（qPCR）检测其胰腺癌组织及6例正常胰腺组织中VEGF mRNA、uPA mRNA定量表达,分析其与临床病理因素之间的关系。结果 VEGF mRNA、uPA mRNA的表达与胰腺癌的组织分化程度、神经侵犯有关。VEGF mRNA在淋巴结转移阳性组中的定量表达高于淋巴结转移阴性组,两组比较差异有统计学意义（t=20.007,P=0.000）;uPA mRNA在直径≤2 cm的肿瘤组织中定量水平小于直径>2 cm的肿瘤组织,两组比较差异有统计学意义（t=7.539,P=0.000）。uPA mRNA在伴有十二指肠侵犯组中的定量表达高于无十二指肠侵犯组,两组比较差异有统计学意义（t=-2.089,P=0.037）。uPA mRNA在Ⅲ期肿瘤组织中的定量表达高于Ⅰ、Ⅱ期肿瘤组织中的定量表达,两组比较差异有统计学意义（t=-9.450,P=...
- 胰腺肿瘤 /
- 血管内皮生长因子A /
- 尿纤溶酶原激活物 /
- 基因表达
Abstract: Objective To investigate the clinical significance of quantitative expression of vascular endothelial growth factor (VEGF) mRNA and urokinase- type plasminogen activator (uPA) mRNA in pancreatic cancer tissue.Methods A retrospective study was conducted on the complete data of 30 patients with a pathological diagnosis of duct adenocarcinoma who were selected from those treated by radical resection of pancreatic head carcinoma from January 2008 to December 2011.Real- time quantitative PCR was used to measure the quantitative expression of VEGF mRNA and uPA mRNA in the pancreatic cancer tissues of the 30 cases and the normal pancreatic tissues of 6 controls, and its relationship with clinicopathological factors was analyzed.Results The quantitative expression of VEGF mRNA and uPA mRNA was correlated with the histological differentiation and perineural invasion of pancreatic cancer.The quantitative expression of VEGF mRNA was significantly higher in patients with lymphatic metastasis than in those without lymphatic metastasis group (t = 20.007, P = 0.000) .The quantitative expression of uPA mRNA was significantly lower in the tumors with a diameter of ≤2 cm than in the tumors with a diameter of > 2 cm (t = 7.539, P = 0.000) .Patients with duodenal invasion had a significantly higher quantitative expression of uPA mRNA than those without duodenal invasion (t =- 2.089, P = 0.037) .The quantitative expression of uPA mRNA in stage III tumor tissues was significantly higher than that of uPA mRNA in stage I and II tumor tissues (t =- 9.450, P = 0.000) .There was a positive correlation between VEGF mRNA expression and uPA mRNA expression (r = 0.334, P = 0.000) .Conclusion The overexpression of VEGF mRNA and uPA mRNA in pancreatic cancer tissue may create an environment that enables the invasion by pancreatic cancer cells.
- pancreatic neoplasms /
- vascular endothelial growth factor A /
- urinary plasminogen activator /
- gene expression

HTML全文

参考文献(17)

[1]XU KC.Investigation of treatment strategy for advanced cancer according to treatment of pancreatic cancer[J].J Clin Hepatol, 2013, 29 (7) :484-488. (in Chinese) 徐克成.从胰腺癌治疗探讨进展期癌症治疗策略[J].临床肝胆病杂志, 2013, 29 (7) :484-488.

[2] JEMAL A, SIEGEL R, XU J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60 (5) :277-300.

[3]LEUNG DW, CACHIANES G, KUANG WJ, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science, 1989, 246 (4935) :1306-1309.

[4]ZORGETTO VA, SILVEIRA GG, OLIVEIRA-COSTA JP, et al.The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinicalpathological features and survival in pancreaticadenocarcinomas[J].Diagn Pathol, 2013, 8:170.

[5]WEIDNER N.Tumoral vasculary as a prognostic factor in cancer patients:the evendence continues to grow[J].J Pathol, 1998, 184 (2) :119-122.

[6]ROGERS A, SMITH MJ, DOOLAN P, et al.Invasive markers identified by gene expression profiling in pancreatic cancer[J].Pancreatology, 2012, 12 (2) :130-140.

[7]HILDENBRAND R, NIEDERGETHMANN M, MARX A, et al.Amplification of theurokinasetype plasm inogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically highrisk group[J].Am J Pathol, 2009, 174 (6) :2246-2253.

[8]DOBRILA-DINTINJANA R, VANIS N, DINTINJANA M, et al.Etiology and oncogenesis of pancreatic carcinoma[J].Coll Antropol, 2012, 36 (3) :1063-1067.

[9]ASUTHKAR S, STEPANOVA V, LEBEDEVA T, et al.Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer[J].Mol Biol Cell, 2013, 24 (17) :2620-2632.

[10]SCHLAEPI JM, WOOD JM.Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors[J].Cancer Metastasis Res, 1999, 18 (4) :473-481.

[11]NIETHAMMER AG, LUBENAU H, MIKUS G, et al.Doubleblind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGFReceptor 2 in patients with stage IV and locally advanced pancreatic cancer[J].BMC Cancer, 2012, 12:361.

[12]HBEL S, KOBURGER I, JOHN M, et al.Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab[J].J Gene Med, 2010, 12 (3) :287-300.

[13]MARTIN LK, LI X, KLEIBER B, et al.VEGF remains an interesting target in advanced pancres cancer (APCA) :results of a multi-institutional phase II study of bevacizumab, gemicitabine, and infusional 5-fluorouracil in patients with APCA[J].Ann Oncol, 2012, 23 (11) :2812-2820.

[14]HILEY CT, CHARD LS, GANGESWARAN R, et al.Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway[J].J Virol, 2013, 87 (5) :2781-2790.

[15]KINDLER HL, NIEDZWIECKI D, HOLLIS D, et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phaseⅢtrial of the Cancer and Leukemia Group B (CALGB 80303) [J].J Clin Oncol, 2010, 28 (22) :3617-3622.

[16]VAN CUTSEM E, VERVENNE WL, BENNOUNA J, et al.PhaseⅢtrial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J].J Clin Oncol, 2009, 27 (13) :2231-2237.

[17]LU JD.Novel therapeutic strategies for advanced pancreatic cancer:targeting the epidermal growth factor and vascular endothelial growth factor pathways[J].China Oncol, 2009, 19 (8) :590-596. (in Chinese) 陆嘉德.晚期胰腺癌的分子靶向治疗[J].中国癌症杂志, 2009, 19 (8) :590-596.

施引文献

资源附件(0)

访问统计